Randomized study with cyclosporine in kidney transplantation: 10-year follow-up.
This study presents the 10-yr follow-up results of a multicenter controlled trial on 108 recipients of cadaveric renal transplantation, randomized to receive cyclosporine (N = 55) or azathioprine (N = 53), both in combination with steroids. The 10-yr patient survival rate was 89% in the cyclosporine group and 83% in the azathioprine group (P = not significant [NS]); the 10-yr graft survival was 56% and 35%, respectively (log-rank test, P = 0.009). The half-life of grafts functioning after 1 yr was 15.4 +/- 3.9 versus 10.6 +/- 3.6, P = NS). The rate of early rejection in the cyclosporine group was significantly lower than that in the azathioprine group (0.30 versus 1.4, P < 0.01). Although the mean creatinine clearance rate was always higher in the azathioprine group, the decline in graft function from the first to the tenth yr was not significantly different between the two groups (-13.0 +/- 16.4 versus -12.3 +/- 19 mL/min, P = NS). In cadaveric renal transplantation, cyclosporine allows better graft survival than azathioprine, not only in the short term but also in the long term, with similar attrition of graft function for up to 10 yr.
Ponticelli
C
C
Divisione di Nefrologia e Dialisi, IRCCS Ospedale Maggiore, Milan, Italy.
Civati
G
G
Tarantino
A
A
Quarto di Palo
F
F
Corbetta
G
G
Minetti
L
L
Vegeto
A
A
Belli
L
L
D000293:Adolescent; D000328:Adult; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D002386:Cataract / Q000139:chemically induced; D002648:Child; D003404:Creatinine / Q000378:metabolism; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007239:Infections / Q000453:epidemiology; D007674:Kidney Diseases / Q000139:chemically induced; D016030:Kidney Transplantation / Q000276:immunology*; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology; D011183:Postoperative Complications / Q000453:epidemiology; D015996:Survival Rate; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D001379:Azathioprine